CAPTRUST Financial Advisors’s Starling Oncology Warrant STLNW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
– Sell
-3,957
Closed -$3K – 5132
2021
Q4
$3K Hold
3,957
– – ﹤0.01% 4309
2021
Q3
$5K Hold
3,957
– – ﹤0.01% 3962
2021
Q2
$7K Sell
3,957
-192
-5% -$258 ﹤0.01% 3723
2021
Q1
$6K Sell
4,149
-688
-14% -$1.28K ﹤0.01% 3676
2020
Q4
$9K Buy
+4,837
New +$8.34K ﹤0.01% 2635

Other funds holding STLNW

CAPTRUST Financial Advisors's STLNW Position: Q1 2022 in Review

CAPTRUST Financial Advisors sold out of Starling Oncology Warrant (STLNW) in Q1 2022, closing a stake of 3,957 shares — an estimated $3K sold.

CAPTRUST Financial Advisors first reported a position in STLNW in Q4 2020 and held it in 5 quarters. The position peaked at $9K in Q4 2020. 12 funds tracked by Wall St. Rank hold STLNW as of Q1 2022.

  • CAPTRUST Financial Advisors reported no remaining Starling Oncology Warrant position as of Q1 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 3,957 Starling Oncology Warrant shares in Q1 2022, an estimated $3K.
  • CAPTRUST Financial Advisors first reported a position in Starling Oncology Warrant in Q4 2020 and held it in 5 quarters.
  • CAPTRUST Financial Advisors's Starling Oncology Warrant position peaked at $9K in Q4 2020.
  • 12 funds tracked by Wall St. Rank held Starling Oncology Warrant as of Q1 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2022, filed 16 May 2022.